AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31822445 — intervention group
Group type: EXPERIMENTAL
Intervention: MINDSET program (multicomponent intervention combining mindfulness and psychoeducation)
Number of subjects: 35
Study 29543473 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-focused cognitive-behavioral therapy (TF-CBT)
Number of subjects: 156
Study 29543473 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 156
Study 29543473 — intervention group
Group type: EXPERIMENTAL
Intervention: TF-CBT
Number of subjects: 156
Study 27334415 — intervention group
Group type: EXPERIMENTAL
Intervention: Rejection treatment including ATG
Number of subjects: 361
Study 27334415 — intervention group
Group type: COMPARATOR
Intervention: Deceased donor kidney transplant
Number of subjects: 361
Study 27334415 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 361
Study 23416349 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity monitoring using an accelerometer (ACC)
Number of subjects: 24
Study 23416349 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day activity recall questionnaire (3-DR)
Number of subjects: 24
Study 23416349 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate (HR) monitor
Number of subjects: 24
Study 23416349 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerometer (ACC) and 3-day activity recall questionnaire (3-DR)
Number of subjects: 24
Study 23705229 — intervention group
Group type: EXPERIMENTAL
Intervention: High-similarity condition
Number of subjects: 63
Study 23705229 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-similarity condition
Number of subjects: 63
Study 20180787 — intervention group
Group type: EXPERIMENTAL
Intervention: OCA (omeprazole, clarithromycin, amoxicillin)
Number of subjects: 460
Study 20180787 — intervention group
Group type: EXPERIMENTAL
Intervention: OLA (omeprazole, levofloxacin, amoxicillin)
Number of subjects: 460
Study 20180787 — intervention group
Group type: EXPERIMENTAL
Intervention: OACM (omeprazole, amoxicillin for 5 days, followed by omeprazole, clarithromycin, metronidazole for 5 days)
Number of subjects: 460
Study 20180787 — intervention group
Group type: EXPERIMENTAL
Intervention: OALM (omeprazole, levofloxacin, amoxicillin for 5 days, followed by omeprazole, levofloxacin, metronidazole for 5 days)
Number of subjects: 460
Study 18706008 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v./i.a. rt‐PA therapy
Number of subjects: 0
Study 18706008 — intervention group
Group type: COMPARATOR
Intervention: i.v. rt‐PA
Number of subjects: 0
Study 18706008 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment arms (i.v./i.a. rt‐PA and i.v. rt‐PA)
Number of subjects: 0
Study 16798444 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural ropivacaine 30 mg diluted to 5 mL (group 5)
Number of subjects: 60
Study 16798444 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural ropivacaine 30 mg diluted to 10 mL (group 10)
Number of subjects: 60
Study 16798444 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural ropivacaine 30 mg diluted to 20 mL (group 20)
Number of subjects: 60
Study 16798444 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural ropivacaine (all groups)
Number of subjects: 60
Study 14672297 — intervention group
Group type: EXPERIMENTAL
Intervention: Meat
Number of subjects: 555
Study 14672297 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy
Number of subjects: 555
Study 14672297 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk
Number of subjects: 555
Study 14672297 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 555
Study 10404948 — intervention group
Group type: EXPERIMENTAL
Intervention: AGT 235T allele presence
Number of subjects: 187
Study 10404948 — intervention group
Group type: COMPARATOR
Intervention: Dietary salt intake (high and low)
Number of subjects: 187
Study 7886996 — intervention group
Group type: EXPERIMENTAL
Intervention: Scintigraphic examination in patients with thigh pain
Number of subjects: 70
Study 7886996 — intervention group
Group type: COMPARATOR
Intervention: Scintigraphic examination in patients without thigh pain
Number of subjects: 70
Study 7886996 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiological analysis in both groups
Number of subjects: 70
Study 2334776 — intervention group
Group type: EXPERIMENTAL
Intervention: Flash preceding sound by 40 milliseconds (AV40)
Number of subjects: 5
Study 2334776 — intervention group
Group type: COMPARATOR
Intervention: Simultaneous flash-click (AV)
Number of subjects: 5
Study 2334776 — intervention group
Group type: COMPARATOR
Intervention: Click (A)
Number of subjects: 5
Study 2334776 — intervention group
Group type: COMPARATOR
Intervention: Flash (V)
Number of subjects: 5
Study 2334776 — intervention group
Group type: EXPERIMENTAL
Intervention: Flash preceding sound by 80 milliseconds (AV80)
Number of subjects: 5
Study 7356683 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 70
Study 7356683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 30237250 — intervention group
Group type: EXPERIMENTAL
Intervention: Colon polyps (in premenopausal women)
Number of subjects: 2004
Study 30237250 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterectomy (in premenopausal women)
Number of subjects: 2004
Study 30237250 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometriosis (in premenopausal women)
Number of subjects: 2004
Study 30237250 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery disease (CVD) (in premenopausal women)
Number of subjects: 2004
Study 30237250 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoporosis (in postmenopausal women)
Number of subjects: 2004
Study 30237250 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypercholesterolemia (in postmenopausal women)
Number of subjects: 2004
Study 30237250 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoarthritis (in postmenopausal women)
Number of subjects: 2004
Study 30237250 — intervention group
Group type: EXPERIMENTAL
Intervention: History of inflammatory bowel disease (in postmenopausal women)
Number of subjects: 2004
Study 27001444 — intervention group
Group type: EXPERIMENTAL
Intervention: ONO-4232 (0.08 ng/kg/min)
Number of subjects: 76
Study 27001444 — intervention group
Group type: EXPERIMENTAL
Intervention: ONO-4232 (0.15 ng/kg/min and above)
Number of subjects: 76
Study 27001444 — intervention group
Group type: EXPERIMENTAL
Intervention: ONO-4232 (various doses)
Number of subjects: 76
Study 27001444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 24198221 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigantol oil (1904 IU once a week)
Number of subjects: 86
Study 24198221 — intervention group
Group type: COMPARATOR
Intervention: Placebo oil
Number of subjects: 86
Study 24198221 — intervention group
Group type: COMPARATOR
Intervention: Vigantol oil (1904 IU once a week) and Placebo oil
Number of subjects: 86
Study 22508200 — intervention group
Group type: EXPERIMENTAL
Intervention: HES (130/0.4) 20 ml/kg + Tranexamic Acid (TA) 10 mg/kg over 30 minutes followed by 1 mg/kg/hr for 12 hours
Number of subjects: 100
Study 22508200 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringer's lactate + TA at same dose
Number of subjects: 100
Study 22508200 — intervention group
Group type: COMPARATOR
Intervention: HES (130/0.4) 20 ml/kg
Number of subjects: 100
Study 22508200 — intervention group
Group type: COMPARATOR
Intervention: Ringer's lactate
Number of subjects: 100
Study 20856830 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 150 μg
Number of subjects: 89
Study 20856830 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 300 μg
Number of subjects: 89
Study 20856830 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol 200 μg
Number of subjects: 89
Study 20856830 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol-fluticasone 50/500 μg
Number of subjects: 89
Study 20856830 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 19235434 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical mitomycin C chemotherapy
Number of subjects: 96
Study 19235434 — intervention group
Group type: COMPARATOR
Intervention: Intravesical BCG immunotherapy
Number of subjects: 96
Study 16698140 — intervention group
Group type: EXPERIMENTAL
Intervention: VO2000 calorimeter
Number of subjects: 33
Study 16698140 — intervention group
Group type: COMPARATOR
Intervention: DELTATRAC
Number of subjects: 33
Study 12842524 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative steroid treatment (protocol group)
Number of subjects: 20
Study 12842524 — intervention group
Group type: COMPARATOR
Intervention: No steroid treatment (control group)
Number of subjects: 20
Study 10595648 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplement (20 ml per day, equivalent to 0.3 g omega‐6, 3.6 g omega‐3; omega‐6/omega‐3 ratio 0.1)
Number of subjects: 60
Study 10595648 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy lecithin supplement (25 g per day, equivalent to 1.5 g omega‐6, 0.5 g omega‐3; omega‐6/omega‐3 ratio 3)
Number of subjects: 60
Study 10595648 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual diet without any supplement)
Number of subjects: 60
Study 8932555 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 77
Study 8932555 — intervention group
Group type: COMPARATOR
Intervention: Control (delayed treatment)
Number of subjects: 77
Study 1954453 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcysteine
Number of subjects: 50
Study 1954453 — intervention group
Group type: COMPARATOR
Intervention: 5% dextrose (Control)
Number of subjects: 50
Study 7041935 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 mg long acting (LA) propranolol
Number of subjects: 20
Study 7041935 — intervention group
Group type: EXPERIMENTAL
Intervention: LA propranolol with carbimazole
Number of subjects: 20
Study 7041935 — intervention group
Group type: EXPERIMENTAL
Intervention: LA propranolol
Number of subjects: 20
Study 7041935 — intervention group
Group type: EXPERIMENTAL
Intervention: LA propranolol and carbimazole
Number of subjects: 20
Study 7041935 — intervention group
Group type: COMPARATOR
Intervention: Carbimazole therapy
Number of subjects: 20
Study 6377221 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral diuretics (chlorothiazide, 20 mg/kg/dose and spironolactone, 1.5 mg/kg/dose, given twice daily)
Number of subjects: 10
Study 6377221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 6377221 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral diuretics
Number of subjects: 10
Study 31563947 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal diet top‐dressed with 19 g of the DFM (PROB)
Number of subjects: 40
Study 31563947 — intervention group
Group type: COMPARATOR
Intervention: Basal diet with no additive (CON)
Number of subjects: 40
Study 29625529 — intervention group
Group type: EXPERIMENTAL
Intervention: Endobronchial coils
Number of subjects: 0
Study 29625529 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SoC)
Number of subjects: 0
Study 26882921 — intervention group
Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Number of subjects: 62
Study 26882921 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural Anesthesia supplemented with General Anesthesia (EpiGA)
Number of subjects: 62
Study 26882921 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 62
Study 24769295 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced fat plus spice (RFS)
Number of subjects: 148
Study 24769295 — intervention group
Group type: COMPARATOR
Intervention: Full fat (FF)
Number of subjects: 148
Study 24769295 — intervention group
Group type: COMPARATOR
Intervention: Reduced fat with no added spice (RF)
Number of subjects: 148
Study 22795099 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 mg soy extract daily for 24 weeks
Number of subjects: 130
Study 22795099 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 mg soy extract daily for 24 weeks
Number of subjects: 130
Study 22795099 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 mg soy extract after 6 months
Number of subjects: 130
Study 22795099 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 mg soy extract after 6 months
Number of subjects: 130
Study 22795099 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 mg soy extract in patients with high bone turnover after 6 months
Number of subjects: 130
Study 22795099 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 mg soy extract in patients with high bone turnover after 6 months
Number of subjects: 130
Study 22795099 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups after 6 months
Number of subjects: 130
Study 20626946 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐Chasqui laboratory information system
Number of subjects: 76
Study 20626946 — intervention group
Group type: COMPARATOR
Intervention: paper system
Number of subjects: 76
Study 18806043 — intervention group
Group type: EXPERIMENTAL
Intervention: IV infusion of phenylephrine and ephedrine combined in a 100% phenylephrine ratio
Number of subjects: 125
Study 18806043 — intervention group
Group type: EXPERIMENTAL
Intervention: IV infusion of phenylephrine and ephedrine combined in a 75% phenylephrine ratio
Number of subjects: 125
Study 18806043 — intervention group
Group type: EXPERIMENTAL
Intervention: IV infusion of phenylephrine and ephedrine combined in a 50% phenylephrine ratio
Number of subjects: 125
Study 18806043 — intervention group
Group type: EXPERIMENTAL
Intervention: IV infusion of phenylephrine and ephedrine combined in a 25% phenylephrine ratio
Number of subjects: 125
Study 18806043 — intervention group
Group type: EXPERIMENTAL
Intervention: IV infusion of phenylephrine and ephedrine combined in a 0% phenylephrine ratio (100% ephedrine)
Number of subjects: 125
Study 18806043 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine alone (control)
Number of subjects: 125
Study 15758912 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (600 mg) administered orally at 15 and 3 hours before ERCP
Number of subjects: 243
Study 15758912 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study 15758912 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (600 mg)
Number of subjects: 243
Study 11803347 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous blood injection (10-20 ml) beneath the staple line
Number of subjects: 16
Study 11803347 — intervention group
Group type: COMPARATOR
Intervention: Control group (only staplers applied)
Number of subjects: 16
Study 10411851 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg BID
Number of subjects: 12
Study 10411851 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 25 mg BID
Number of subjects: 12
Study 10411851 — intervention group
Group type: COMPARATOR
Intervention: Hoe‐140 (bradykinin antagonist) after enalapril
Number of subjects: 12
Study 10411851 — intervention group
Group type: COMPARATOR
Intervention: Hoe‐140 (bradykinin antagonist) after losartan
Number of subjects: 12
Study 7769294 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily primaquine
Number of subjects: 0
Study 7769294 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily doxycycline
Number of subjects: 0
Study 7769294 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly mefloquine
Number of subjects: 0
Study 7769294 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine plus proguanil
Number of subjects: 0
Study 7769294 — intervention group
Group type: COMPARATOR
Intervention: Daily vitamin alone
Number of subjects: 0
Study 2178964 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol (0.15 mg.kg‐1 x 2; 30 min apart) (n = 87)
Number of subjects: 176
Study 2178964 — intervention group
Group type: COMPARATOR
Intervention: Intravenous salbutamol (5 micrograms.kg‐1) (n = 89)
Number of subjects: 176
Study 2178964 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (3‐6 mg.kg‐1) infused i.v. 60 min after salbutamol treatment
Number of subjects: 176
Study 2178964 — intervention group
Group type: COMPARATOR
Intervention: Cross-over study on 18 patients
Number of subjects: 176
Study 6776300 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally administered zomepirac sodium at 100 mg
Number of subjects: 109
Study 6776300 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally administered zomepirac sodium at 200 mg
Number of subjects: 109
Study 6776300 — intervention group
Group type: COMPARATOR
Intervention: IM administered morphine sulfate at 8 mg
Number of subjects: 109
Study 30719796 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention to increase perceived control over pain
Number of subjects: 228
Study 30719796 — intervention group
Group type: COMPARATOR
Intervention: Pain
Number of subjects: 228
Study 30719796 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived control over pain
Number of subjects: 228
Study 28286249 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory muscle stretching (TG)
Number of subjects: 28
Study 28269449 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable gastric electric stimulator with automatic daily activity compliance reporting
Number of subjects: 4
Study 24829951 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-Solving Therapy (PST)
Number of subjects: 970
Study 24829951 — intervention group
Group type: COMPARATOR
Intervention: Waitlist
Number of subjects: 970
Study 22430968 — intervention group
Group type: EXPERIMENTAL
Intervention: PA-824 50 mg
Number of subjects: 15
Study 22430968 — intervention group
Group type: EXPERIMENTAL
Intervention: PA-824 100 mg
Number of subjects: 15
Study 22430968 — intervention group
Group type: EXPERIMENTAL
Intervention: PA-824 150 mg
Number of subjects: 15
Study 22430968 — intervention group
Group type: EXPERIMENTAL
Intervention: PA-824 200 mg
Number of subjects: 15
Study 22430968 — intervention group
Group type: COMPARATOR
Intervention: HRZE (Control)
Number of subjects: 15
Study 18848765 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (SQ) Acthar Gel (20 units)
Number of subjects: 0
Study 18848765 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (SQ) Acthar Gel (80 units)
Number of subjects: 0
Study 18848765 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular (IM) Acthar Gel (20 units)
Number of subjects: 0
Study 18848765 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular (IM) Acthar Gel (80 units)
Number of subjects: 0
Study 17449974 — intervention group
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser therapy combined with SRP
Number of subjects: 10
Study 17449974 — intervention group
Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 10
Study 15678732 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 57
Study 15678732 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 57
Study 15678732 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 57
Study 11122543 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban (100 microg/kg bolus plus 3 microg/kg/min infusion for 72 hours)
Number of subjects: 117
Study 11122543 — intervention group
Group type: COMPARATOR
Intervention: Heparin (5000 U intravenous bolus, 1000 U/h infusion)
Number of subjects: 117
Study 11122543 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban
Number of subjects: 117
Study 11122543 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 117
Study 11122543 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban and alteplase
Number of subjects: 117
Study 9352988 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic vasodilator therapy
Number of subjects: 45
Study 9352988 — intervention group
Group type: COMPARATOR
Intervention: Discontinuation of vasodilators
Number of subjects: 45
Study 8441105 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedure A (two fractional doses after removal from ventilator)
Number of subjects: 299
Study 8441105 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedure B (two fractional doses through a neonatal suction valve without removal from ventilator)
Number of subjects: 299
Study 8441105 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedure C (four fractional doses during removal from ventilator)
Number of subjects: 299
Study 2887195 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine 60 mg
Number of subjects: 9
Study 2887195 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 31042301 — intervention group
Group type: COMPARATOR
Intervention: SAPP training
Number of subjects: 39
Study 31042301 — intervention group
Group type: COMPARATOR
Intervention: SAPP + PERT training
Number of subjects: 39
Study 28259274 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethyl chloride spray
Number of subjects: 151
Study 28259274 — intervention group
Group type: COMPARATOR
Intervention: Routine injection (no topical spray)
Number of subjects: 151
Study 26210612 — intervention group
Group type: EXPERIMENTAL
Intervention: X:IT multi-component school-based programme
Number of subjects: 4041
Study 26210612 — intervention group
Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 4041
Study 23954277 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 198
Study 23954277 — intervention group
Group type: EXPERIMENTAL
Intervention: GCSB-5
Number of subjects: 198
Study 21658093 — intervention group
Group type: EXPERIMENTAL
Intervention: Suspension formulation of omeprazole in 8.4% sodium bicarbonate
Number of subjects: 10
Study 21658093 — intervention group
Group type: COMPARATOR
Intervention: MUPS® formulation of omeprazole disintegrated in water
Number of subjects: 10
Study 18083272 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg)
Number of subjects: 378
Study 18083272 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 378
Study 16427852 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass grafting (OPCAB)
Number of subjects: 50
Study 16427852 — intervention group
Group type: COMPARATOR
Intervention: Conventional on-pump coronary artery bypass grafting (CABG)
Number of subjects: 50
Study 12968636 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 0
Study 10930970 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (medicine review and education programme)
Number of subjects: 0
Study 10930970 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 10930970 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (medicine education)
Number of subjects: 0